BRIEF published on 09/16/2026 at 07:35, 1 month 15 days ago Sensorion is considering an initial public offering in the United States Biotechnology Initial Public Offering DRY Sensory Auditory Therapies
BRIEF published on 09/16/2026 at 07:35, 1 month 15 days ago Sensorion soumet un projet d'offre publique initiale Biotechnologie Introduction En Bourse Dépôt Auprès De La SEC Audiologie Sensorion
PRESS RELEASE published on 09/16/2026 at 07:30, 1 month 15 days ago Informations privilégiées / Autres communiqués Sensorion annonce le dépôt confidentiel du projet de document d’enregistrement auprès de la SEC en vue d’une potentielle introduction en bourse aux Etats-Unis Biotechnologie Introduction En Bourse Sensorion Dépôt Confidentiel Restaurer L'audition
PRESS RELEASE published on 09/16/2026 at 07:30, 1 month 15 days ago Inside Information / Other news releases Sensorion announces submission of draft registration statement to SEC for potential U.S. IPO. Company focuses on novel therapies for hearing loss disorders SEC Sensorion Hearing Loss Therapies Draft Registration Statement U.S. IPO
BRIEF published on 09/15/2026 at 07:35, 1 month 16 days ago Sensorion Completes Reverse Share Split Biotechnology Shareholder Compensation Reverse Share Split Hearing Loss Therapies Euronext Growth Market
BRIEF published on 09/15/2026 at 07:35, 1 month 16 days ago Sensorion finalise son regroupement d'actions inversé. Biotechnologie Fractionnement Inversé Des Actions Rémunération Des Actionnaires Thérapies Pour La Perte Auditive Marché De Croissance Euronext
PRESS RELEASE published on 09/15/2026 at 07:30, 1 month 16 days ago Inside Information / Other news releases Sensorion completes reverse share split, exchanging 50 existing shares for 1 new share with €5 par value. New shares listed on Euronext Growth market in Paris under ISIN code FR001401A9Z0 Shareholder Compensation ISIN Code Reverse Share Split Sensorion Euronext Growth Market
BRIEF published on 09/03/2026 at 07:35, 1 month 28 days ago Sensorion receives authorization to initiate a clinical trial in France Gene Therapy Clinical Trial France Hearing Sensory
BRIEF published on 09/03/2026 at 07:35, 1 month 28 days ago Sensorion Receives Approval for SENS-601 Trial in France Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-601
BRIEF published on 09/03/2026 at 07:35, 1 month 28 days ago Sensorion obtient l'autorisation de mener un essai clinique du SENS-601 en France. Essai Clinique Thérapie Génique Sensorion Perte Auditive SENS-601
Published on 10/30/2026 at 23:35, 2 days ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 4 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 8 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 13 hours 14 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 18 hours 49 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 7 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 1 hour ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 2 days ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
